Chemical Information
Antiviral agent ID	DrugRepV_2111
Antiviral agent name	NITD008
IUPAC Name	(2R,3R,4R,5R)-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3-ethynyl-5-(hydroxymethyl)oxolane-3,4-diol
SMILES (canonical)	C#CC1(C(C(OC1N2C=CC3=C2N=CN=C3N)CO)O)O
SMILES (isomeric)	C#C[C@]1([C@@H]([C@H](O[C@H]1N2C=CC3=C2N=CN=C3N)CO)O)O
Molecular Formula	C13H14N4O4
Molecular Weight (g/mol)	290.279
InChl	InChI=1S/C13H14N4O4/c1-2-13(20)9(19)8(5-18)21-12(13)17-4-3-7-10(14)15-6-16-11(7)17/h1,3-4,6,8-9,12,18-20H,5H2,(H2,14,15,16)/t8-,9-,12-,13-/m1/s1
Synonyms	7-Deaza-2'-C-ethynyladenosine | 7-(2-C-Ethynyl-?-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine
Structural Information
Clinical Information
Category	Antiviral
Biological Information
Secondary Indication	Zika virus (ZIKV) NA GZ01/2016
Secondary Indication (Approaches)	Experimental
Secondary Indication (Methods)	in-vivo
Secondary Indication (Model system) [cell lines/ animal models]	AG129
Secondary Indication (Mode of viral infection)	Adsorption
Secondary Indication (Viral titer)	100000 PFU
Secondary Indication (Mode of drug delivery)	Intraperitoneal
Secondary Indication (Time of drug delivery)	After infection
Secondary Indication (Duration of drug delivery)	3 days
Secondary Indication (Drug concentration)	50 mg/kg/day
Secondary Indication (Cell based assay)	Survival assay
Secondary Indication (Change)	Increase
Secondary Indication (Type of Inhibition)	Percentage survival [ NA NA ]
Secondary Indication (Survival rate)	50
Reference	Deng YQ, Zhang NN, Li CF, Tian M, Hao JN, Xie XP, Shi PY, Qin CF..Adenosine Analog NITD008 Is a Potent Inhibitor of Zika Virus..Open Forum Infect Dis. 2016 Aug 30;3(4):ofw175. eCollection 2016 Oct. PMID:27747251
Comment	NITD008 is potent inhibitor of ZIKV and can be used as reference inhibitor for future ZIKV antiviral drug screen and discovery.